自动胰岛素输送技术在糖尿病中的作用
本文综述了糖尿病自动胰岛素输送系统的应用扩展。混合闭环系统已用于1型糖尿病常规临床实践,真实世界数据反映其性能与临床试验一致。文章还讨论了2型糖尿病等新兴适应症、可及性与实施问题、现有系统局限性及创新改进方法。
要点
- 混合闭环系统已用于1型糖尿病常规临床实践
- 真实世界数据反映其性能与临床试验一致
- 新兴适应症包括日间胰岛素需求变异大的2型糖尿病
核心结论
- 自动胰岛素输送系统在糖尿病中的作用正在扩大,混合闭环系统已用于1型糖尿病常规临床实践。
研究设计与样本
- 综述,检索范围未在原文中报告。
主要发现
- 真实世界数据反映了混合闭环系统在临床试验中观察到的性能和可用性。
- 混合闭环系统的新兴适应症包括日间胰岛素需求变异大的2型糖尿病及其他具有挑战性的应用。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文讨论了现有闭环系统的局限性,但未在摘要中具体列出。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The role of automated insulin delivery systems in diabetes is expanding. Hybrid closed-loop systems are being used in routine clinical practice for treating people with type 1 diabetes. Encouragingly, real-world data reflects the performance and usability observed in clinical trials. We review the commercially available hybrid closed-loop systems, their distinctive features and the associated real-world data. We also consider emerging indications for closed-loop systems, including the treatment of type 2 diabetes where variability of day-to-day insulin requirements is high, and other challenging applications for this technology. We discuss issues around access and implementation of closed-loop technology, and consider the limitations of present closed-loop systems, as well as innovative approaches that are being evaluated to improve their performance.
引用
- Boughton CK, Hovorka R. The role of automated insulin delivery technology in diabetes. Diabetologia. 2024. PMID: 38740602. doi:10.1007/s00125-024-06165-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。